Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome.

Beksac M, Cengiz Seval G, Kanellias N, Coriu D, Rosiñol L, Ozet G, Goranova-Marinova V, Unal A, Bila J, Ozsan H, Ivanaj A, Balić LI, Kastritis E, Bladé J, Dimopoulos MA.

Haematologica. 2019 Jul 5. pii: haematol.2019.219295. doi: 10.3324/haematol.2019.219295. [Epub ahead of print]

2.

PET with Fluorodeoxyglucose F 18/Computed Tomography as a Staging Tool in Multiple Myeloma.

Seval GC, Ozkan E, Beksac M.

PET Clin. 2019 Jul;14(3):369-381. doi: 10.1016/j.cpet.2019.03.009. Epub 2019 Apr 12. Review.

PMID:
31084776
3.

A comparative safety review of histone deacetylase inhibitors for the treatment of myeloma.

Cengiz Seval G, Beksac M.

Expert Opin Drug Saf. 2019 Jul;18(7):563-571. doi: 10.1080/14740338.2019.1615051. Epub 2019 May 9. Review.

PMID:
31070945
4.

Current approach to early gastrointestinal and liver complications of hematopoietic stem cell transplantation.

Atilla E, Ataca Atilla P, Cengiz Seval G, Bektaş M, Demirer T.

Turk J Gastroenterol. 2019 Feb;30(2):122-131. doi: 10.5152/tjg.2018.18156. Review.

5.

The safety of bortezomib for the treatment of multiple myeloma.

Cengiz Seval G, Beksac M.

Expert Opin Drug Saf. 2018 Sep;17(9):953-962. doi: 10.1080/14740338.2018.1513487. Epub 2018 Aug 30. Review.

PMID:
30118610
6.

Current Approach to Non-Infectious Pulmonary Complications of Hematopoietic Stem Cell Transplantation.

Cengiz Seval G, Topçuoğlu P, Demirer T.

Balkan Med J. 2018 Mar 15;35(2):131-140. doi: 10.4274/balkanmedj.2017.1635. Review.

7.

Gonadotoxic Effects of Nilotinib in Chronic Myeloid Leukemia Treatment Dose in a Mouse Model.

Cengiz Seval G, Özkavukçu S, Seval M, Aylı M.

Turk J Haematol. 2017 Jun 5;34(2):137-142. doi: 10.4274/tjh.2016.0092. Epub 2016 Jul 28.

8.

Xanthelasma palpebrarum: a new side effect of nilotinib.

Sayin I, Ayli M, Oğuz AK, Seval GC.

BMJ Case Rep. 2016 Jan 12;2016. pii: bcr2015213511. doi: 10.1136/bcr-2015-213511.

9.

Ruxolitinib Treatment in a Patient with Primary Myelofibrosis Resistant to Conventional Therapies and Splenectomy: A Case Report.

Aylı M, Özcan M, Cengiz Seval G.

Turk J Haematol. 2015 Jun;32(2):180-3. doi: 10.4274/tjh.2013.0338.

10.

Treatment of Acute Myeloid Leukemia in Adolescent and Young Adult Patients.

Seval GC, Ozcan M.

J Clin Med. 2015 Mar 11;4(3):441-59. doi: 10.3390/jcm4030441. Review.

11.

Sirolimus based immunosuppression is associated with need for early repeat therapeutic ERCP in liver transplant patients with anastomotic biliary stricture.

Tabibian JH, Girotra M, Yeh HC, Segev DL, Gulsen MT, Cengiz-Seval G, Singh VK, Cameron AM, Gurakar A.

Ann Hepatol. 2013 Jul-Aug;12(4):563-9.

12.

HTK preservative solution is associated with increased biliary complications among patients receiving DCD liver transplants: a single center experience.

Gulsen MT, Girotra M, Cengiz-Seval G, Price J, Singh VK, Segev DL, Cameron AM, Gurakar A.

Ann Transplant. 2013 Feb 20;18:69-75. doi: 10.12659/AOT.883831.

PMID:
23792504
13.

Blood donors and factors impacting the blood donation decision: motives for donating blood in Turkish sample.

Karacan E, Cengiz Seval G, Aktan Z, Ayli M, Palabiyikoglu R.

Transfus Apher Sci. 2013 Dec;49(3):468-73. doi: 10.1016/j.transci.2013.04.044. Epub 2013 May 23.

PMID:
23706312
14.

Sirolimus may be associated with early recurrence of biliary obstruction in liver transplant patients undergoing endoscopic stenting of biliary strictures.

Tabibian JH, Yeh HC, Singh VK, Cengiz-Seval G, Cameron AM, Gurakar A.

Ann Hepatol. 2011 Jul-Sep;10(3):270-6.

Supplemental Content

Loading ...
Support Center